Chlamydia and Gonorrhea

Women’s Health | Wellness

CHLAMYDIA AND GONORRHEA

In the US, Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (Ng) are some of the most common and treatable sexually transmitted diseases. CDC has reported an increase in chlamydia cases at 4.7% and gonorrhea cases at 18.5% since 2015. CDC stated any individual who has sex is at risk.1 Some groups are more affected, including young people aged 15-24.1

CDC and ACOG Testing Recommendations Most Are Asymptomatic The Centers for Disease Control and Prevention (CDC) and the Chlamydial infection is often referred to as a “silent” disease American College of Obstetricians and Gynecologists (ACOG) because thousands of people are infected and have no recommend Ct and Ng testing for sexually active women each symptoms5; in fact, approximately 75% of infected women do not year until age 251 and for older high-risk women (eg, those who experience symptoms.6 Young women (ages 15-24) account for have a new sex partner or multiple sex partners).2,3 nearly half (46%) of reported cases.1 Gonorrhea infections often do not produce symptoms in women until complications like Women who present with a new occurrence of cervicitis should pelvic inflammatory disease (PID) have occurred.2 be tested for Ct and Ng with nucleic acid amplification technology (NAAT).2 Women with cervicitis should be evaluated for bacterial vaginosis and trichomoniasis.2 Failure to Diagnose and Treat Can Lead to Serious Women age 25 and older are at increased risk if they have Complications a new sex partner, more than one sex partner, a sex partner with concurrent partners, or a sex partner who has a sexually • Untreated Ct infection increases risk for PID, ectopic transmitted infection. Women who test positive should be pregnancy, infertility, and HIV transmission and acquisition.6 retested at 3 months.4 • Untreated Ng infection increases risk for PID, infertility, ectopic pregnancy, epididymitis, and HIV transmission.7 • Infertility affects 20,000 women each year due to undiagnosed STDs.1

WELLNESS at EVERY age. Detect More Infections with NAATs LabCorp offers the Aptima Combo 2® assay for simultaneous detection and differentiation of Chlamydia trachomatis and Neisseria gonorrhoeae employing nucleic acid amplification technology (NAAT). NAATs are recognized by the CDC as the most sensitive tests for Ct and more sensitive than culture for Ng.2

Test Performance by Specimen Type8 Specimen Type Sensitivity Ct Specificity Ct Sensitivity Ng Specificity Ng ThinPrep liquid-based Pap 96.7% 99.2% 92.3% 99.8%

Vaginal Swab (clinician collected) 96.6% 96.8% 96.0% 99.2%

Endocervical Swab 94.2% 97.6% 99.2% 98.7% Urine (Female) 94.7% 98.9% 91.3% 99.3%

Convenient Test Options LabCorp offers Ct and Ng test options from numerous collection devices, giving clinicians and patients convenient options: ThinPrep® Liquid-based Pap; Aptima® Vaginal swabs. Test No. Test Name 183194 Chlamydia/Gonococcus, NAA 180021 NuSwab® Vaginitis Plus (VG+), Test includes: Bacterial Vaginosis by NAA (Atopobium vaginae, BVAB-2, Megasphaera-1), C albicans and C glabrata by NAA, Trichomonas vaginalis by NAA, Chlamydia trachomatis by NAA, Neisseria gonorrhoeae by NAA 199320 Gynecologic Pap Test (Image-guided), Liquid-based Preparation and Chlamydia/Gonococcus, NAA With Reflex to Human Papillomavirus (HPV)(Aptima®) When ASC-U 199325 Gynecologic Pap Test (Image-guided), Liquid-based Preparation and Chlamydia/Gonococcus/Trichomonas, NAA With Reflex to Human Papillomavirus (HPV) (Aptima®) When ASC-U 199310 Gynecologic Pap Test (Image-guided), Liquid-based Preparation and Chlamydia/Gonococcus, NAA and Human Papillomavirus (HPV) (Aptima®) With Reflex to HPV Genotypes 16 and 18,45 *For the most current information regarding test options, including specimen requirements, please consult the online Test Menu at www.LabCorp.com.

References 1. Centers for Disease Control and Prevention. CDC fact sheet: Reported STDs in the United States, 2016. Available at: http://www.cdc.gov/std/stats16. Accessed December 4, 2017. 2. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR. 2015 June 5;64(3):1-138. 3. The American College of Obstetricians and Gynecologists. Primary and Preventive Care: Periodic Assessments. Committee Opinion No 483. Obstet Gynecol. 2011 Apr; 117(4):1008-1014. 4. Centers for Disease Control and Prevention. 2015 Screening recommendations. Available at: http://www.cdc.gov/std/screening-recommendations.htm. Accessed December 5, 2017. 5. Centers for Disease Control and Prevention. Chlamydia-CDC fact sheet (detailed). Available at: http://www.cdc.gov/std/chlamydia/stdfact-chlamydia-detailed.htm. Accessed October 2, 2015. 6. National Committee for Quality Assurance. The State of Health Care Quality 2011: HEDIS Measures of Care. Washington, DC: NCQA; 2011. 7. Centers for Disease Control and Prevention. Gonorrhea Fact Sheet. Available at http://www.cdc.gov/std/gonorrhea/gonorrhea-fact-sheet.pdf. Accessed September 14, 2015. 8. Gen-Probe® Aptima Combo 2® Assay [package insert]. San Diego, Calif: Gen-Probe Incorporated; 2008.

Visit the online Test Menu at www.LabCorp.com for full test information, including specimen collection requirements.

ThinPrep® is a registered trademark of Hologic Inc. Aptima® and Aptima Combo 2® are registered trademarks of Gen-Probe Inc. ©2018 Laboratory Corporation of America® Holdings All rights reserved. L18012-0318-1